1st Zantac Case Against GSK Dropped by Plaintiff

Joseph Bayer, the plaintiff in the first case surrounding GSK’s Zantac has voluntarily dismissed his case against the company, citing personal health reasons. Bayer sued GSK and several others for esophageal cancer he developed that he and his care team attributed to the drug. So far, he has gotten a combined settlement of half a million dollars from the other companies. The dismissal isn’t a true win for GSK, however, as Bayer has a year to refile the case.

According to Kevin Dunleavy, “Two years ago, Zantac was pulled from the market when it was linked to unacceptable levels of N-nitrosodimethylamine, a potential cancer-causing agent, sparking a wave of litigation against the developer of the drug, Boehringer Ingelheim, and its former commercial partners GSK and Sanofi. Last week, GSK and Sanofi insisted that there was no scientific evidence that Zantac causes cancer, both pointing out that the level of carcinogen contained in the drug is lower than the amounts found in common foods such as packaged meats and frozen fish.”

To read more, click here.

(Source: Fierce Pharma, August 16th, 2022)